RPL5 and cancer: The Cancer Genome Atlas (TCGA) pan-cancer analyses identified RPL5 and RPL22 as significantly mutated in glioblastoma multiforme (GBM, 2.8%) and uterine corpus endometrial carcinoma (UCEC, 10.9%) respectively [6–9], and inactivating RPL22 mutations have also been described in colorectal and gastric cancer [10, 11].